Bacteria Chassis for Synthetic Biology
Client Satisfaction with Bacterial Chassis Is Our Pursuit
CD BioGlyco constructs a variety of Chassis Cells including Plant Cells, Insect Cells, bacterial cells, Mammalian Cells and synthesizes a wide range of glycoconjugates to support synthetic biology. Bacterial cells are excellent hosts for the production of a wide range of high-value-added natural products. We offer many types of bacterial chassis cell engineering services and bacterial chassis cells producing a variety of saccharides to meet our client's research needs. Based on the re-engineering of bacteria, we enable them to perform functions that they would not normally perform in their natural environment.
Based on our extensive experience in Chassis Development, we use a variety of techniques to modify a wide range of bacteria. The bacterial mutants obtained by transformation do not produce any major endogenous secondary metabolites. They are used as chassis for efficient heterologous gene expression at a higher level than natural producers, resulting in the production of unnatural metabolites and exogenous natural. We use two main strategies to develop microbial chassis: a bottom-up approach (genome synthesis) and a top-down approach (genome reduction):
- Bottom-up approach
- We self-assemble bacterial chassis cells from scratch. Proficient use of DNA synthesis allows us to completely reconstruct entire genomes and new bacterial chassis.
- Top-down approach
- We reduce the genome by removing unnecessary cellular genes in a strategy to understand genome structure and improve its characterization. Based on large-scale DNA analysis and comparative analysis of genomes, we identify genes that are indispensable for cellular life as well as similar and/or significantly different metabolic pathways. Afterward, we use different strategies to achieve deletions, introductions, and other modifications, including transposons, the use of site-specific recombinases, plasmid- and linear DNA-mediated procedures, and the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system.
We further subdivide our bacterial chassis engineering services for synthetic biology into the following to better support our client's research needs. In addition to these bacterial chassis, we also offer corresponding Carbohydrate Products.
- E. coli is a model strain for the study of physiology, microbial geneticsand metabolism. It is one of the most important chassis cells due to its clear genetic background and variety of tools for genetic manipulation. CD BioGlyco provides a high-quality E. coli engineering service to meet our clients' research needs.
- C. jejuni is widely researched and used as a chassis cell in synthetic biology. CD BioGlyco provides C. jejuni engineering service based on a complete genome editing operating system to support synthetic biology research, such as CRISPR/Cas system.
- B. natto is one of the most commonly used chassis cells. CD BioGlyco utilizes gene knockout and other technologies to alter the metabolic pathways of B. natto to increase the production of target products, reduce the production of by-products or toxic and hazardous substances, and rationalize the distribution of energy flow.
- As a non-model bacterium, Halomonas has become a competitive platform for the production of a wide range of products such as proteins, chemicals, etc. CD BioGlyco provides a high-quality Halomonas engineering service based on a variety of genetic tools and computational simulations.
- CD BioGlyco provides a C. glutamicum engineering service based on a variety of genetic manipulation systems, including homologous recombination-mediated gene editing systems, CRISPR-Cas9, and other technologies, which have been developed for use with C. glutamicum.
- Streptomycetaceae is a new type of synthetic biology tool, CD BioGlyco provides targeted modification of Streptomycetaceae through gene knockout, insertion, and site-directed mutagenesis.
- Z. mobilis is a parthenogenetic anaerobic Gram-negative bacterium that has the advantages of low pH tolerance, high ethanol yield, fast glucose metabolism rate, and the ability to tolerate high concentrations of ethanol. CD BioGlyco has perfected the genetic tools such as genome editing related to Z. mobilis engineering.
- B. subtilis is a model strain with a robust protein expression system. CD BioGlyco employs a variety of research strategies and technologies, including gene editing systems, genetic circuits, and spatial scaffolds to design and construct B. subtilis chassis cells.
- Actinomycetes have a large genome that encodes multiple clusters of secondary metabolite biosynthesis genes. CD BioGlyco employs multiple construction strategies to construct Actinomycetes chassis cells for different purposes.
- P. putida is a ubiquitous Gram-negative soil bacterium that meets many of the criteria for constructing synthetic biology chassis, including metabolic diversity, robustness, ease of manipulation, etc. CD BioGlyco offers a one-stop P. putida engineering service for synthetic biology.
Based on the research needs of our clients, we construct bacterial chassis cells that efficiently utilize a wide range of substrates, especially inexpensive raw materials, with high yields of target products, few by-products, and stability on a safe basis.
Publication Data
Technology: Top-down approach, Bottom-up approach
Journal: Synthetic and Systems Biotechnology
IF: 1.335
Published: 2019
Results: This paper describes in detail advances in the engineering, modification, and application of chassis for synthetic microorganisms, including bacteria, and presents two construction strategies. Bacterial chassis cells (E. coli, B. subtilis, etc.) for synthetic biology were successfully constructed by these two strategies.
Fig.1 A strategy for microbial chassis construction. (Chi, et al., 2019)
Frequently Asked Questions
- What is the minimal genome and what is its importance for bacterial chassis development?
A minimal genome is a collection of the smallest number of genes necessary to sustain cell growth and reproduction under optimal conditions. Ideal bacterial chassis cells should be stable, robust, and of low complexity, with a streamlined, robust genomic structure (i.e., minimal genome) to improve the controllability and maneuverability of the designed system and reduce the complexity of the research problem.
- Which techniques are used for bacterial chassis cell development?
Identification of essential and non-essential genes is achieved by analytical techniques such as metabolic network modeling, gene database comparison, and experimental methods such as genomic CRISPRi and RNA interference methods. In the modification of genes, commonly used techniques include CRISPR-Cas system-mediated gene editing, λ-Red homologous recombination system, Cre-loxP recombination system, and so on.
Applications
- Bacterial chassis offer a promising alternative for the efficient and sustainable production of sugar compounds.
- Bacterial chassis are used to screen novel drug compounds and have important applications in the pharmaceutical field.
- Bacterial chassis are used to reconstruct processes such as natural development, helping to advance research in chemistry, waste treatment, agriculture, and more.
Highlights of Us
- We develop a wide variety of bacterial chassis cells that survive under various conditions, thereby expanding their range of applications.
- We target the modification of bacteria through gene insertion, knockout, targeted mutagenesis, gene replacement, and other manipulations.
- During the development of bacterial chassis cells, we focus on regulatory and signaling pathways and their associated effects on cellular processes and downstream production, as well as maximizing the yield of sugar products.
CD BioGlyco offers promising alternatives for efficient and sustainable carbohydrate production through the development of a wide range of chassis cells. Please feel free to contact us for more detailed information on bacterial chassis.
References
- Chi, H.; et al. Engineering and modification of microbial chassis for systems and synthetic biology. Synthetic and Systems Biotechnology. 2019, 4(1): 25-33.
For research use only. Not intended for any clinical use.
Related Services
